Skip to content
The Nexus
DossierENTITY

Nippon Shinyaku

Coverage of Nippon Shinyaku in the Nexus archive.

Earliest in view: May 8 · 13:37 UTCMost recent: May 8 · 18:32 UTC
Co-mentioned in this coverage
Capricor Therapeuticsorganization2NS Pharmaorganization2Duchenne muscular dystrophytopic2Medicaretopic1Medicaidtopic1deramioceltopic1FDAorganization1Alex Hoganperson1Lizzy Lawrenceperson1
Recent coverage
  • HEALTHMay 8 · 18:32 UTCSTAT NEWS
    STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug

    Capricor Therapeutics accuses Nippon Shinyaku of failing to follow through on marketing plans for a Duchenne muscular dystrophy treatment. A pricing glitch in their distribution agreement would make the therapy economically impractical for patients covered by Medicare, Medicaid, and private insurers. The issue was disclosed in March 2025.

  • HEALTHMay 8 · 13:37 UTCSTAT NEWS
    STAT+: The biotech news you need to read today

    Capricor Therapeutics is suing its partner Nippon Shinyaku over the launch of its Duchenne therapy, claiming they botched preparations and created an inaccessible pricing structure. The biotech company is fighting for its promising treatment, deramiocel. This lawsuit may impact the accessibility of the treatment for patients.